We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$61.5B
1-Year Est. Return
30.7%
This Fund
S&P 500
This Quarter
Est. Return
+6.3%
1 Year Est. Return
+30.7%
3 Year Est. Return
+96.89%
5 Year Est. Return
+121.97%
10 Year Est. Return
+542.41%
AUM
$31.9B
AUM Growth
+$1.95B
(+6.5%)
Cap. Flow
+$433M
Cap. Flow
% of AUM
1.36%
Top 10 Holdings %
Top 10 Hldgs %
19.72%
Holding
2,075
New
328
Increased
694
Reduced
841
Closed
117
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Illumina
ILMN
|
+$152M |
| 2 |
Ventas
VTR
|
+$139M |
| 3 |
Williams Companies
WMB
|
+$122M |
| 4 |
Healthpeak Properties
DOC
|
+$100M |
| 5 |
Chevron
CVX
|
+$78.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$276M |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
+$110M |
| 3 |
Fortune Brands Innovations
FBIN
|
+$84.2M |
| 4 |
AGN
Allergan Inc
AGN
|
+$73.4M |
| 5 |
Morgan Stanley
MS
|
+$66.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.6% |
| 2 | Consumer Staples | 12.46% |
| 3 | Energy | 12.05% |
| 4 | Financials | 8.62% |
| 5 | Utilities | 8.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
AbbVie
ABBV
$471B
| $244M | 0.76% |
4,317,840
+268,769
| +7% | +$14.1M |
|
27
Eli Lilly
LLY
$1.09T
| $231M | 0.72% |
3,714,961
+27,532
| +0.7% | +$1.64M |
|
|
RDS.B
28
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
| $227M | 0.71% |
2,608,560
+66,473
| +3% | +$5.53M |
|
29
GSK
GSK
$106B
| $227M | 0.71% |
3,388,348
+695,757
| +26% | +$47.1M |
|
|
30
Illumina
ILMN
$29.3B
| $215M | 0.68% |
1,239,340
+1,015,670
| +454% | +$152M |
|
31
LyondellBasell Industries
LYB
$19.6B
| $204M | 0.64% |
2,085,111
-83,939
| -4% | -$7.99M |
|
32
Halliburton
HAL
$26.1B
| $203M | 0.64% |
2,851,848
-175,387
| -6% | -$11.2M |
|
33
American Electric Power
AEP
$71.2B
| $190M | 0.6% |
3,414,779
+27,839
| +0.8% | +$1.47M |
|
34
Procter & Gamble
PG
$338B
| $187M | 0.59% |
2,377,247
+571,899
| +32% | +$46.1M |
|
35
DexCom
DXCM
$29.3B
| $177M | 0.55% |
17,803,392
-91,668
| -0.5% | -$812K |
|
36
Alkermes
ALKS
$8.14B
| $176M | 0.55% |
3,499,276
-55,315
| -2% | -$2.55M |
|
37
JPMorgan Chase
JPM
$929B
| $173M | 0.54% |
2,995,471
-475,946
| -14% | -$26.8M |
|
38
Pfizer
PFE
$144B
| $157M | 0.49% |
5,591,960
-536,317
| -9% | -$15.3M |
|
39
PepsiCo
PEP
$197B
| $156M | 0.49% |
1,745,937
+9,603
| +0.6% | +$829K |
|
|
SLXP
40
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $150M | 0.47% |
1,213,894
-215,278
| -15% | -$23.8M |
|
|
CBST
41
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $147M | 0.46% |
2,100,334
-432,994
| -17% | -$29.5M |
|
42
Corning
GLW
$107B
| $135M | 0.42% |
6,140,399
-37,527
| -0.6% | -$796K |
|
|
SLCA
43
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $133M | 0.42% |
2,390,736
-535,630
| -18% | -$25.2M |
|
44
Biogen
BIIB
$30.8B
| $132M | 0.42% |
419,779
-4,158
| -1% | -$1.25M |
|
|
DYAX
45
DELISTED
DYAX CORPORATION
DYAX
| $130M | 0.41% |
13,584,600
-1,059,137
| -7% | -$8.07M |
|
46
Bristol-Myers Squibb
BMY
$130B
| $129M | 0.41% |
2,662,800
-4,212
| -0.2% | -$208K |
|
47
Hartford Financial Services
HIG
$39.9B
| $128M | 0.4% |
3,573,439
+436,858
| +14% | +$15.4M |
|
48
NXP Semiconductors
NXPI
$62.7B
| $126M | 0.4% |
1,904,700
-173,200
| -8% | -$10.6M |
|
49
Gilead Sciences
GILD
$167B
| $122M | 0.38% |
1,473,732
+22,973
| +2% | +$1.79M |
|
50
CVS Health
CVS
$136B
| $114M | 0.36% |
1,515,334
-13,676
| -0.9% | -$1.03M |
|
Similar funds
Federated Hermes's Q2 2014 Portfolio in Review
As of Q2 2014, Federated Hermes held 2,075 positions worth $31.9B, up 6.5% from $29.9B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Federated Hermes's Q2 2014 filing shows 328 new, 694 increased, 841 reduced and 117 closed positions. Its largest new stake was ATHLON ENERGY INC COM: 939,555 shares worth $44.8M. The largest sale was AstraZeneca, an estimated $276M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, down from 17% a quarter earlier, followed by Consumer Staples and Energy.
- Federated Hermes's largest Q2 2014 buy was ATHLON ENERGY INC COM: 939,555 shares worth $44.8M.
- Federated Hermes added most to Illumina in Q2 2014, an estimated $152M increase.
- Federated Hermes's biggest Q2 2014 reduction was AstraZeneca, cutting an estimated $276M.
- Federated Hermes fully exited SIEMENS AKTIENGESELLSCHAFT ADS in Q2 2014, selling an estimated $39.7M.
- Federated Hermes's ten largest holdings make up 20% of its $31.9B portfolio in Q2 2014.
- Federated Hermes opened 328 new positions and closed 117 in Q2 2014.
- Federated Hermes's portfolio value rose 6.5% quarter-over-quarter to $31.9B.
Based on Federated Hermes's 13F filing for Q2 2014, filed 7 Aug 2014.